<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: We explored whether <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) risk and the effects of <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> differed in subjects with and without <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and according to various features of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> defined by the Adult Treatment Panel III (ATP III) in subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in the <z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> Intervention and Event Lowering in <z:mp ids='MP_0002055'>Diabetes</z:mp> (FIELD) study </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: The prevalence of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and its features was calculated </plain></SENT>
<SENT sid="2" pm="."><plain>Cox proportional models adjusted for age, sex, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> status, and baseline A1C levels were used to determine the independent contributions of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> features to total <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> event rates and the effects of <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: More than 80% of FIELD participants met the ATP III criteria for <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Each ATP III feature of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, apart from increased waist circumference, increased the absolute risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> events over 5 years by at least 3% </plain></SENT>
<SENT sid="5" pm="."><plain>Those with marked <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> (elevated <z:chebi fb="4" ids="17855">triglycerides</z:chebi> &gt;or=2.3 mmol/l and <z:hpo ids='HP_0003233'>low HDL cholesterol</z:hpo>) were at the highest risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> (17.8% over 5 years) </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> significantly reduced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> events in those with <z:hpo ids='HP_0003233'>low HDL cholesterol</z:hpo> or <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The largest effect of <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> to reduce <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk was observed in subjects with marked <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> in whom a 27% relative risk reduction (95% CI 9-42, P = 0.005; number needed to treat = 23) was observed </plain></SENT>
<SENT sid="8" pm="."><plain>Subjects with no prior <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> had greater risk reductions than the entire group </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">Metabolic syndrome</z:e> components identify higher <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk in individuals with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, so the absolute benefits of <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> are likely to be greater when <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> features are present </plain></SENT>
<SENT sid="10" pm="."><plain>The highest risk and greatest benefits of <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> are seen among those with marked <z:hpo ids='HP_0002155'>hypertriglyceridemia</z:hpo> </plain></SENT>
</text></document>